In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid ...

Find out if gene therapy has also find its way into skin diseases. With two approvals in the last 2 years, is it the start of ...

CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia ...

Abeona Therapeutics transitions to a commercial-stage company with ZEVASKYN's FDA approval, QTC activation, and a PRV sale boosting operations toward ...

ZEVASKYN TM (prademagene zamikeracel) is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis ...

On April 29, 2025, Abeona announced approval from the U.S. Food and Drug Administration (FDA) for ZEVASKYN as the first and only autologous cell-based gene therapy for the treatment of wounds in ...

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority ...

Abeona earned the voucher two weeks ago, when the FDA cleared a cell therapy called Zevaskyn for a form of epidermoloysis bullosa, a rare skin condition. That approval, Abeona’s first, was critical ...